"Ranbaxy's performance is not a surprise. Most of us were fundamentally negative on the outcome of quarterly numbers."

"One cannot have some reaction in the stock price in the couple of days or maybe week to follow but then it will get price adjusted."

In a chat with ET Now, Sonam Udasi, Head of Research, IDBI Capital, shares his views on Ranbaxy.

"Finally, the good times are here for Ranbaxy. It has a potential to be into the 1000 category in about 18 months' time."

Net sales was down to Rs 2,633.20 crore for the quarter ended June, as against Rs 3,204.59 crore in the corresponding period last year.

Ranbaxy’s September quarter performance, which was sans the exclusivity sales of generic Lipitor, was boosted by two authorised generic lau...

Ranbaxy is expected to report a 33 per cent jump in its net sales for the quarter ended September 30 to Rs 2698 crore.

While Ranbaxy did secure the final approval of the USFDA to launch the generic version of Lipitor on time, there are too many players to sp...

The US FDA allowed Ranbaxy to make and sell atorvastatin tablets, the chemical name of Lipitor, ending months of uncertainty.

Ranbaxy would have a tendency to jump up. So maybe 10% fall from here, it would be a good buy opportunity to get into Ranbaxy.

Ranbaxy Laboratories, India's largest company by sales, is expected to start supplying raw materials for anti-ulcer drug esomeprazole magne...

Given the attractive valuations at current levels, Reliance Money has upgraded its rating on Ranbaxy Laboratories from ‘hold’ to ‘buy’ with...

Shares of Ranbaxy Laboratories continued to witness fresh selling pressure on Friday. The stock was trading at Rs 164, losing another 4% in...

India's largest drugmaker, Ranbaxy Laboratories, has missed its December 2008 deadline to launch an anti-migraine drug as the US regulator ...

Ranbaxy may shift production of the $1.5-billion drug Valacyclovir to its other FDA- approved facilities. The Top 10 food myths revealed | ...

UBS has downgraded its ratings on Ranbaxy from "neutral" to "sell", citing the ongoing investigation by the US Food and Drug Administration...

Pharma major Ranbaxy Laboratories on Tuesday said the acquisition of Be-Tabs Pharmaceuticals (Pty) Ltd (Be-Tabs) has been further strengthe...